Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

A Prospective, Multi-Center, Non-Randomized Clinical Study of the BARD® COVERA Arteriovenous (AV) Stent Graft in the Treatment of Stenosis in the Venous Outflow of AV Fistula Access Circuits (AVeNEW) Post Approval Study

The objective of this study is to collect post-market, real-world safety and effectiveness data of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit.

Study Overview

• Status: Active, not recruiting
• Conditions: Arteriovenous Fistula
• Intervention / Treatment: Device: Covera Vascular Covered Stent

Detailed Description

Prospective, multi-center, non-randomized clinical study designed to assess the long-term safety and effectiveness of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the AV access circuit of hemodialysis subjects dialyzing with an arteriovenous (AV) fistula.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85012
      • Arizona Kidney Disease and Hypertension Center Medical Research Services
  • Connecticut
    • New Haven, Connecticut, United States, 06511
      • Yale University
  • Illinois
    • Westmont, Illinois, United States, 60559
      • Chicago Access Care
  • Massachusetts
    • West Springfield, Massachusetts, United States, 01089
      • Kidney Care & Transplant Services of New England
  • Michigan
    • Flint, Michigan, United States, 48507
      • Michigan Vascular Center
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • University of Minnesota Medical Center
    • New Brighton, Minnesota, United States, 55112
      • Minnesota Vascular and Surgery Center
  • North Carolina
    • Raleigh, North Carolina, United States, 27610
      • North Carolina Nephrology
  • Rhode Island
    • Providence, Rhode Island, United States, 02906
      • Providence Access Care
  • Texas
    • Dallas, Texas, United States, 75208
      • Dallas Renal Group
    • San Antonio, Texas, United States, 78216
      • San Antonio Kidney and Disease Access Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Clinical Inclusion Criteria

1. Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.
2. Subject must be either a male or non-pregnant female ≥ 21 years of age with an expected lifespan sufficient to allow for completion of all study procedures.
3. Subject must be willing to comply with the protocol requirements, including clinical and telephone follow-up.
4. Subject must have an upper extremity AV fistula that has undergone at least one successful dialysis session with two-needle cannulation, prior to the index procedure.
5. Subject must have angiographic evidence of a stenosis ≥ 50% (by visual estimation) located in the venous outflow of the AV access circuit and present with clinical or hemodynamic evidence of AV fistula dysfunction.
6. The target lesion must be ≤ 9cm in length. Note: multiple stenoses may exist within the target lesion.
7. The reference vessel diameter of the adjacent non-stenotic vein must be between 5.0 and 9.0mm.

Exclusion Criteria:

Clinical Exclusion Criteria

1. The subject is dialyzing with an AV graft.
2. The target lesion has had a corresponding thrombosis treated within 7 days prior to the index procedure.
3. The hemodialysis access is located in the lower extremity.
4. The subject has an infected AV fistula or uncontrolled systemic infection.
5. The subject has a known uncontrolled blood coagulation/bleeding disorder.
6. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.
7. The subject has a known hypersensitivity to nickel-titanium (Nitinol) or tantalum.
8. The subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
9. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.
10. Additional stenotic lesions (≥ 50%) in the venous outflow that are > 3cm from the edge of the target lesion and are not successfully treated (defined as ≤ 30% residual stenosis) prior to treating the target lesion.
11. An aneurysm or pseudoaneurysm is present within the target lesion.
12. The location of the target lesion would require the COVERATM Vascular Covered Stent be deployed across the elbow joint.
13. The target lesion is located within a stent.
14. The location of the target lesion would require that the COVERA™ Vascular Covered Stent be deployed at or across the segment of fistula utilized for dialysis needle puncture (i.e., "cannulation zone").
15. The location of the target lesion would require that the COVERA™ Vascular Covered Stent be placed in the central veins (subclavian, brachiocephalic, Superior Vena Cava (SVC)) or under the clavicle at the thoracic outlet.
16. There is incomplete expansion of an appropriately sized angioplasty balloon to its expected profile, in the operator's judgment, during primary angioplasty at the target lesion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: COVERA Vascular Covered Stent; COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.	Device: Covera Vascular Covered Stent; This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety through 30 days	Freedom from any adverse event(s), localized or systemic, that reasonably suggest the involvement of the AV access circuit that require or result in any of the following alone or in combination: additional interventions, in-patient hospitalization or prolongation of an existing hospitalization; or death.	Through 30 days following index procedure
Target Lesion Primary Patency (TLPP)	The interval following the index intervention until the next clinically driven reintervention at or adjacent to the original treatment site, or until the extremity is abandoned for permanent access.	1, 3, 6, 12, 18, 24, and 36 months following post-index procedure
Access Circuit Primary Patency (ACPP)	The interval following the index intervention until the next access thrombosis or repeated intervention.	1, 3, 6, 12, 18, 24, and 36 months post index procedure
Rate of Device and Procedure Related Adverse Events involving the access circuit	Rate of device and procedure related adverse events (AEs) involving the access circuit.	1, 3, 6, 12, 18, 24, and 36 months post index procedure.
Total Number of Arteriovenous (AV) Access Circuit Reinterventions	Number of reinterventions to the arteriovenous (AV) access circuit until access abandonment or through study completion.	1, 3, 6, 12, 18, 24, and 36 months post index procedure
Total Number of Target Lesion Reinterventions	Number of reinterventions to maintain target lesion patency	1, 3, 6, 12, 18, 24, and 36 months post index procedure
Index of Patency Function (IPF)	Time from the index study procedure to study completion or access abandonment divided by the number of visits for a reintervention performed on the arteriovenous (AV) access circuit in order to maintain vascular access for hemodialysis.	1, 3, 6, 12, 18, 24, and 36 months post index procedure
Index of Patency Function for Target Lesion	Time from the index study procedure to study completion or complete access abandonment divided by the number of visits for a reintervention performed at the target lesion in order to maintain vascular access for hemodialysis.	1, 3, 6, 12, 18, 24, and 36 months post index procedure
Post-Intervention Secondary Patency	The interval after the index intervention until the access is abandoned.	1, 3, 6, 12, 18, 24, and 36 months post index procedure
Acute Technical Success for Stent Graft Placement	Defined as the successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure.	At time of index procedure
Acute Procedural Success	Defined as anatomic success and resolution of the pre-procedural clinical indicator(s) (clinical success) of a hemodynamically significant stenosis	At time of index procedure

Collaborators and Investigators

• Sponsor: C. R. Bard
• Investigators: Principal Investigator: Bart Dolmatch, M.D., The Palo Alto Medical Foundation

Study record dates

Study Major Dates

• Study Start (Actual): July 3, 2020
• Primary Completion (Estimated): November 18, 2025
• Study Completion (Estimated): November 18, 2025

Study Registration Dates

• First Submitted: February 6, 2020
• First Submitted That Met QC Criteria: February 6, 2020
• First Posted (Actual): February 10, 2020

Study Record Updates

• Last Update Posted (Actual): April 16, 2024
• Last Update Submitted That Met QC Criteria: April 15, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Congenital Abnormalities; Pathological Conditions, Anatomical; Cardiovascular Abnormalities; Vascular Malformations; Arteriovenous Malformations; Vascular Fistula; Fistula; Arteriovenous Fistula
• Other Study ID Numbers: BDPI-19-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No